Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Odonate Therapeutics Announces Closing of Initial Public Offering

Odonate Therapeutics,Inc.
Posted on: 11 Dec 17

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $24.00 per share. The aggregate gross proceeds from the initial public offering to Odonate were approximately $150 million, before deducting underwriting discounts and commissions and offering expenses. The shares began trading on the NASDAQ Global Select Market on December 7, 2017 under the ticker symbol “ODT.”

Goldman Sachs & Co. LLC and Jefferies acted as joint book-running managers for the offering. Cowen also acted as a bookrunner for the offering.

A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission (SEC) on December 6, 2017. This offering was made only by means of a prospectus, final copies of which may be obtained from Goldman Sachs & Co. LLC (Attention Prospectus Department, 200 West Street, New York, NY 10282; telephone: 866-471-2526); Jefferies LLC (Attention Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022; telephone: 877-821-7388); or Cowen and Company, LLC (c/o Broadridge Financial Services, Attention Prospectus Department, 1155 Long Island Avenue, Edgewood, NY, 11717; telephone: 631-274-2806).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. The Company’s initial focus is on the development of tesetaxel, a novel, orally administered chemotherapy agent belonging to the taxane class. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

View source version on

Business Wire

Last updated on: 11/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.